Cite
Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
MLA
Lauren Jones, and Alan M. Jones. “Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug Class Dipeptidyl-Peptidase IV Inhibitors (DPP4i): Can Polypharmacology Help Explain?” Pharmacology Researchperspectives, vol. 10, no. 6, Sept. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....30a4ca7915c43f1bd234b711fa987ae6&authtype=sso&custid=ns315887.
APA
Lauren Jones, & Alan M. Jones. (2022). Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? Pharmacology Researchperspectives, 10(6).
Chicago
Lauren Jones, and Alan M. Jones. 2022. “Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug Class Dipeptidyl-Peptidase IV Inhibitors (DPP4i): Can Polypharmacology Help Explain?” Pharmacology Researchperspectives 10 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....30a4ca7915c43f1bd234b711fa987ae6&authtype=sso&custid=ns315887.